Investigational Drug Details
| Drug ID: | D549 |
| Drug Name: | SGLT2 inhibitor |
| Synonyms: | -- |
| Type: | Chemical drug |
| DrugBank ID: | -- |
| DrugBank Description: | -- |
| PubChem ID: | -- |
| CasNo: | -- |
| Repositioning for NAFLD: | No |
| SMILES: | -- |
| InChiKey: | -- |
| Molecular Weight: | -- |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | SGLT2 inhibitor |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Clinical trial on-going (JPRN-UMIN000027362) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0062 | NCT03867487 | Phase 2 | Active, not recruiting | No Results Available | May 1, 2019 | March 4, 2022 | Details |
| L0066 | NCT02649465 | Phase 4 | Completed | No Results Available | November 11, 2015 | July 2, 2021 | Details |
| L0082 | NCT02696941 | Phase 1 | Completed | No Results Available | February 2016 | May 4, 2018 | Details |
| L0345 | NCT05232071 | Phase 2 | Not yet recruiting | No Results Available | June 1, 2022 | March 2, 2022 | Details |
| L0373 | NCT05147090 | Phase 4 | Not recruiting | No Results Available | 22/11/2021 | 21 December 2021 | Details |
| L0545 | JPRN-UMIN000027362 | Not selected | Not Recruiting | No Results Available | 16/05/2017 | 2 April 2019 | Details |
| L0546 | JPRN-UMIN000027304 | Not selected | Not Recruiting | Has Results | 15/05/2017 | 17 May 2021 | Details |
| L0547 | JPRN-UMIN000027337 | Not selected | Recruiting | No Results Available | 14/05/2017 | 2 April 2019 | Details |
| L0573 | JPRN-UMIN000023574 | Not applicable | Not Recruiting | No Results Available | 09/08/2016 | 2 April 2019 | Details |
| L0593 | JPRN-UMIN000020544 | Not selected | Not Recruiting | No Results Available | 13/01/2016 | 21 May 2019 | Details |
| L0607 | JPRN-UMIN000018166 | Not selected | Recruiting | No Results Available | 02/07/2015 | 13 July 2020 | Details |
| L0703 | KCT0004923 | Not applicable | Recruiting | No Results Available | 16/04/2020 | 21 April 2020 | Details |
| L0821 | TCTR20170511001 | Phase 4 | Not Recruiting | Has Results | 11/05/2017 | 7 February 2022 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00001 | 35259705 | Diabetes Metab Syndr | Role of diabetologists in the management of nonalcoholic fatty liver disease: Primary prevention and screening/management of fibrosis and cirrhosis. | Details |
| A00217 | 35181350 | Diabetes Res Clin Pract | Metabolic Changes Induced by Dapagliflozin, an SGLT2 Inhibitor, in Japanese Patients with Type 2 Diabetes Treated by Oral Anti-diabetic Agents: A Randomized, Clinical Trial. | Details |
| A00249 | 35166009 | Diabetes Obes Metab | Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes. | Details |
| A00609 | 35030323 | Lancet Gastroenterol Hepatol | Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. | Details |
| A01065 | 34882949 | Diabetes Obes Metab | Elevated liver enzymes and comorbidities in type 2 diabetes: A multicentre analysis of 51 645 patients from the Diabetes Prospective Follow-up (DPV) database. | Details |
| A01613 | 34680463 | Biomedicines | Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges. | Details |
| A01811 | 34606980 | Endocr Pract | Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials. | Details |
| A02363 | 34402473 | Eur J Gastroenterol Hepatol | Glucagon is associated with NAFLD inflammatory progression in type 2 diabetes, not with NAFLD fibrotic progression. | Details |
| A02567 | 34326946 | World J Diabetes | Exploring new treatment options for polycystic ovary syndrome: Review of a novel antidiabetic agent SGLT2 inhibitor. | Details |
| A02827 | 34227216 | Diabetes Obes Metab | Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin. | Details |
| A02838 | 34224699 | Eur J Pharmacol | Dapagliflozin attenuates steatosis in livers of high-fat diet-induced mice and oleic acid-treated L02 cells via regulating AMPK/mTOR pathway. | Details |
| A02848 | 34220701 | Front Endocrinol (Lausanne) | Effect of SGLT2 Inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. | Details |
| A02857 | 34214406 | Expert Opin Investig Drugs | Anti-diabetic drugs and NASH: from current options to promising perspectives. | Details |
| A03370 | 34027265 | Hepatol Commun | Impact of Sodium Glucose Cotransporter 2 Inhibitors on Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus. | Details |
| A03740 | 33882758 | Expert Rev Clin Pharmacol | Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease. | Details |
| A03753 | 33877366 | Diabetologia | Liver-targeting drugs and their effect on blood glucose and hepatic lipids. | Details |
| A03789 | 33862461 | Biochem Biophys Res Commun | Canagliflozin ameliorates hepatic fat deposition in obese diabetic mice: Role of prostaglandin E2. | Details |
| A03850 | 33847462 | Hepatol Res | Meta-analysis of the effect of sodium-glucose cotransporter 2 inhibitors on hepatic fibrosis in patients with type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease. | Details |
| A03995 | 33798599 | Eur J Pharmacol | Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH. | Details |
| A04359 | 33648515 | Cardiovasc Diabetol | Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study. | Details |